Disease · HP_0012450
Chronic constipation
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Chronic constipation. Diseases, record HP_0012450. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0012450
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Chronic constipation
- Open Targets ID
- HP_0012450
- Other names
- Infrequent bowel movements
- Highest stage of its drugs
- Phase 3, for 4 of its 12 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs12
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LINACLOTIDE | CHEMBL3301675 | Protein | Phase 3 | ClinicalTrials.gov | 8 | 8 | 8 | Drugs and targets |
| PRUCALOPRIDE | CHEMBL117287 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| POLYETHYLENE GLYCOL 3350 | CHEMBL1201479 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| LACTULOSE | CHEMBL296306 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| LUBIPROSTONE | CHEMBL1201134 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| LINACLOTIDE ACETATE | CHEMBL3301676 | Protein | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| POLYETHYLENE GLYCOL | CHEMBL1201478 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| RELAMORELIN | CHEMBL4297525 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 1 | Drugs and targets |
| ITOPRIDE | CHEMBL2107457 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DOMPERIDONE | CHEMBL219916 | Small molecule | Unknown | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
1 to 10 of 12
See all 12 drugsTargets7
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| DRD2 | D(2) dopamine receptor | 2 | Dopamine D2 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/1813 | Drugs and targets |
| ACHE | Acetylcholinesterase | 1 | Acetylcholinesterase inhibitor | Phase 2 | https://conductscience.org/library/genes/43 | Drugs and targets |
| CLCN2 | Chloride channel protein 2 | 1 | Chloride channel protein 2 opener | Phase 2/3 | https://conductscience.org/library/genes/1181 | Drugs and targets |
| GHSR | Growth hormone secretagogue receptor type 1 | 1 | Ghrelin receptor agonist | Phase 2 | https://conductscience.org/library/genes/2693 | Drugs and targets |
| GUCY2C | Guanylyl cyclase C | 1 | Heat-stable enterotoxin receptor agonist | Phase 3 | https://conductscience.org/library/genes/2984 | Drugs and targets |
| HTR4 | 5-hydroxytryptamine receptor 4 | 1 | Serotonin 4 (5-HT4) receptor agonist | Phase 3 | https://conductscience.org/library/genes/3360 | Drugs and targets |
| SLC10A2 | Ileal sodium/bile acid cotransporter | 1 | Ileal bile acid transporter inhibitor | Unknown | https://conductscience.org/library/genes/6555 | Drugs and targets |
Trials30
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00730171 | An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation | Phase 3 | 1,743 | 2018-02-19 | Irritable Bowel Syndrome With Constipation, Chronic Constipation | LINACLOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00765999 | An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation | Phase 3 | 1,559 | 2019-02-15 | Chronic Constipation, Irritable Bowel Syndrome With Constipation | LINACLOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00730015 | Trial of Linaclotide in Patients With Chronic Constipation | Phase 3 | 643 | 2013-01-30 | Chronic Constipation | LINACLOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00765882 | Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation | Phase 3 | 633 | 2013-01-30 | Chronic Constipation | LINACLOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01642914 | Safety and Efficacy of Linaclotide in Patients With Chronic Constipation and Prominent Abdominal Bloating | Phase 3 | 487 | 2016-04-26 | Chronic Constipation, Constipation | LINACLOTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01147926 | Evaluation of Prucalopride in Male Subjects With Chronic Constipation. | Phase 3 | 374 | 2014-09-09 | Male Subjects With Chronic Constipation | PRUCALOPRIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00402337 | Dose-range-finding, Phase 2 Trial of Oral Linaclotide Acetate Administered to Patients With Chronic Constipation | Phase 2 | 310 | 2013-03-05 | Chronic Constipation | LINACLOTIDE ACETATE | Its record names the disease | ClinicalTrials.gov |
| NCT01190020 | Effect of Lubiprostone on Methanogenesis and Bowel Function in Chronic Constipation. | Phase 1 | 41 | 2019-01-15 | Chronic Constipation, Methanogenesis | LUBIPROSTONE | Its record names the disease | ClinicalTrials.gov |
| NCT01447849 | Lubiprostone and Mucus Secretion in Patients With Chronic Constipation | Phase 2/3 | 40 | 2013-09-23 | Constipation | LUBIPROSTONE | Its record names the disease | ClinicalTrials.gov |
| NCT01469819 | Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation | Phase 2/3 | 37 | 2016-08-01 | Chronic Idiopathic Constipation | LUBIPROSTONE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 30
See all 30 trialsComparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Linaclotide (CC) vs Linaclotide (IBS-C): Number of Participants With at Least One Treatment-Emergent Adverse Events (TEAEs) | 399 of 523 | 748 of 1,032 | 1,555 | NCT00765999 | Trial comparisons |
| Linaclotide (CC) vs Linaclotide (IBS-C): serious adverse events | 31 of 523 | 57 of 1,032 | 1,555 | NCT00765999 | Trial comparisons |
| PRUCALOPRIDE vs PLACEBO: serious adverse events | 1 of 184 | 4 of 186 | 370 | NCT01147926 | Trial comparisons |
| Lubiprostone vs Placebo: serious adverse events | 0 of 29 | 0 of 12 | 41 | NCT01190020 | Trial comparisons |
Papers from its trials14
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 39664231 | DERIVED | 2 | PubMed |
| 34585675 | DERIVED | 2 | PubMed |
| 33428631 | DERIVED | 1 | PubMed |
| 30084233 | DERIVED | 1 | PubMed |
| 27650225 | DERIVED | 1 | PubMed |
| 26467700 | DERIVED | 1 | PubMed |
| 26222318 | DERIVED | 1 | PubMed |
| 26001337 | DERIVED | 1 | PubMed |
| 25869393 | DERIVED | 1 | PubMed |
| 25617726 | DERIVED | 1 | PubMed |
1 to 10 of 14
See all 14 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0012450
GET https://conductscience.org/api/diseases/v1/HP_0012450/trials?page=2